Theravance Biopharma Stock Price

0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Theravance Biopharma Inc TBPH NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 7.29 20:00:00
Open Price Low Price High Price Close Price Prev Close
Bid Price Ask Price Spread News
7.27 7.36 0.09 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 7.29 USD


Draw Mode:

Theravance Biopharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 535.60M 73.47M 41.81M $ 71.86M $ - -4.47 -1.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -60.75k 7.30%

more financials information »

Theravance Biopharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TBPH Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week6.947.456.757.15567,4090.355.04%
1 Month8.339.086.107.422,194,673-1.04-12.48%
3 Months14.3314.916.108.981,306,421-7.04-49.13%
6 Months20.5622.746.1011.16795,795-13.27-64.54%
1 Year16.0222.746.1013.34576,355-8.73-54.49%
3 Years31.2135.486.1018.11393,272-23.92-76.64%
5 Years37.0043.446.1021.66337,668-29.71-80.3%

Theravance Biopharma Description

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. It develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.